Ultragenyx Pharmaceutical Inc. Weighted Average Number of Shares Outstanding, Diluted from Q1 2017 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q1 2017 to Q3 2025.
  • Ultragenyx Pharmaceutical Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2025 was 99.8M shares, a 4.48% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 90.5M shares, a 23.1% increase from 2023.
  • Ultragenyx Pharmaceutical Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 73.5M shares, a 5.19% increase from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 69.9M shares, a 3.13% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)

Ultragenyx Pharmaceutical Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 99.8M +4.28M +4.48% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 98.5M +11.9M +13.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 96.3M +12M +14.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 90.5M +17M +23.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-19
Q3 2024 95.5M +23.8M +33.3% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 86.6M +15.7M +22.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 84.3M +13.9M +19.8% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 73.5M +3.63M +5.19% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-19
Q3 2023 71.7M +1.61M +2.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 70.9M +973K +1.39% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 70.4M +852K +1.23% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q4 2022 69.9M Oct 1, 2022 Dec 31, 2022 10-K 2025-02-19
Q3 2022 70.1M +2.18M +3.21% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 69.9M +2.32M +3.43% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 69.5M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q3 2021 67.9M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 67.6M +6.46M +10.6% Apr 1, 2021 Jun 30, 2021 10-Q 2021-08-03
Q2 2020 61.1M +3.63M +6.31% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q2 2019 57.5M Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-30
Q1 2019 53.2M +4.13M +8.42% Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-07
Q1 2018 49.1M +7.24M +17.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q1 2017 41.8M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08

Ultragenyx Pharmaceutical Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 90.5M +17M +23.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-19
2023 73.5M +3.63M +5.19% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-19
2022 69.9M +2.12M +3.13% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-19
2021 67.8M +6.95M +11.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 60.8M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.